Tourmaline Bio (TRML) Projected to Post Quarterly Earnings on Monday

Tourmaline Bio (NASDAQ:TRML) is anticipated to announce its Q1 2025 earnings results before the market opens on Monday, May 12th. Analysts expect Tourmaline Bio to post earnings of ($0.91) per share for the quarter.

Tourmaline Bio (NASDAQ:TRML) last issued its earnings results on Friday, May 2nd. The company reported ($0.89) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.02. On average, analysts expect Tourmaline Bio to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Tourmaline Bio Stock Performance

NASDAQ TRML opened at $15.09 on Friday. The stock has a market capitalization of $387.59 million, a P/E ratio of -5.35 and a beta of 2.11. The business’s fifty day moving average is $15.49 and its two-hundred day moving average is $18.71. Tourmaline Bio has a 1 year low of $11.56 and a 1 year high of $29.79.

Analysts Set New Price Targets

TRML has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Tourmaline Bio in a research report on Monday, May 5th. Chardan Capital reissued a “buy” rating and issued a $70.00 target price on shares of Tourmaline Bio in a research report on Monday, May 5th. Lifesci Capital began coverage on shares of Tourmaline Bio in a research report on Monday, February 24th. They issued an “outperform” rating and a $58.00 price target for the company. Finally, Wedbush lifted their price objective on shares of Tourmaline Bio from $42.00 to $43.00 and gave the stock an “outperform” rating in a research report on Friday, March 14th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, Tourmaline Bio presently has an average rating of “Buy” and a consensus price target of $49.33.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.